Journal of minimally invasive gynecology · 2025
Onabotulinumtoxin A Injections for Patients With Pelvic Floor Dysfunction.
СтатьяОбзорVideo-Audio MediaНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Whitmore Gabrielle T, Tam Jenny, Orlando Megan S
Аннотация
STUDY OBJECTIVE: To review the current literature surrounding onabotulinum toxin A injections for patients with pelvic floor dysfunction and to show how to perform these injections.
SETTING: Academic tertiary care hospital DESIGN: It is estimated that about 50% to 90% of patients with chronic pelvic pain have pain that originates from myofascial sources, including the pelvic floor muscles. In patients with pelvic floor dysfunction, management consists of pelvic floor physical therapy with the addition of pelvic floor trigger point injections with a local anesthetic as needed. We offer onabotulinum toxin A to individuals who require long-term repeat trigger point injections, have barriers to accessing monthly injections, or show no durable improvement.
INTERVENTION: We show a comprehensive pelvic floor exam and techniques for administering of onabotulinum toxin A to pelvic floor muscles in individuals with pelvic floor dysfunction, as well as a demonstration on a live patient. We perform an exam while the patient is awake, either in the clinic or at the time of the procedure, and examine the pubococcygeus, iliococcygeus, and obturator internus muscles to assess for hypertonicity and tenderness to palpation. Once sedation is initiated, 200 units of onabotulinum toxin A are then reconstituted with 20 mL of normal saline. The pudendal nerve kit allows for 1 cm depth of penetration with the needle. Approximately 1 to 2 mL of onabotulinumtoxin A are injected sequentially in multiple locations along the above-mentioned pelvic floor muscles. Medication effects may last up to 3 to 6 months, with a reduction in pain scores starting at 6 weeks and lasting through 12 weeks based on published literature. Adverse effects may include constipation, urinary incontinence, urinary tract infections, fecal incontinence, or urinary retention.
CONCLUSIONS: Onabotulinumtoxin A may be helpful in patients with refractory pelvic floor dysfunction. We show how to perform these injections with a safe and reproducible technique.
VIDEO ABSTRACT: Video: Onabotulinumtoxin A may be helpful in patients with refractory pelvic floor dysfunction, and we demonstrate how to perform these injections safely.
SETTING: Academic tertiary care hospital DESIGN: It is estimated that about 50% to 90% of patients with chronic pelvic pain have pain that originates from myofascial sources, including the pelvic floor muscles. In patients with pelvic floor dysfunction, management consists of pelvic floor physical therapy with the addition of pelvic floor trigger point injections with a local anesthetic as needed. We offer onabotulinum toxin A to individuals who require long-term repeat trigger point injections, have barriers to accessing monthly injections, or show no durable improvement.
INTERVENTION: We show a comprehensive pelvic floor exam and techniques for administering of onabotulinum toxin A to pelvic floor muscles in individuals with pelvic floor dysfunction, as well as a demonstration on a live patient. We perform an exam while the patient is awake, either in the clinic or at the time of the procedure, and examine the pubococcygeus, iliococcygeus, and obturator internus muscles to assess for hypertonicity and tenderness to palpation. Once sedation is initiated, 200 units of onabotulinum toxin A are then reconstituted with 20 mL of normal saline. The pudendal nerve kit allows for 1 cm depth of penetration with the needle. Approximately 1 to 2 mL of onabotulinumtoxin A are injected sequentially in multiple locations along the above-mentioned pelvic floor muscles. Medication effects may last up to 3 to 6 months, with a reduction in pain scores starting at 6 weeks and lasting through 12 weeks based on published literature. Adverse effects may include constipation, urinary incontinence, urinary tract infections, fecal incontinence, or urinary retention.
CONCLUSIONS: Onabotulinumtoxin A may be helpful in patients with refractory pelvic floor dysfunction. We show how to perform these injections with a safe and reproducible technique.
VIDEO ABSTRACT: Video: Onabotulinumtoxin A may be helpful in patients with refractory pelvic floor dysfunction, and we demonstrate how to perform these injections safely.